KR101274543B1 - 인간 아드레날린 β３ 수용체 리간드, 이를 포함하는 식품 및 의약품 - Google Patents

인간 아드레날린 β３ 수용체 리간드, 이를 포함하는 식품 및 의약품 Download PDF

Info

Publication number
KR101274543B1
KR101274543B1 KR1020117000640A KR20117000640A KR101274543B1 KR 101274543 B1 KR101274543 B1 KR 101274543B1 KR 1020117000640 A KR1020117000640 A KR 1020117000640A KR 20117000640 A KR20117000640 A KR 20117000640A KR 101274543 B1 KR101274543 B1 KR 101274543B1
Authority
KR
South Korea
Prior art keywords
acid
component
fat
cells
unsaturated fatty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117000640A
Other languages
English (en)
Korean (ko)
Other versions
KR20110017437A (ko
Inventor
야수오 푸지모토
쇼이치 구리하라
타다오 하마야
Original Assignee
리콤 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리콤 코포레이션 filed Critical 리콤 코포레이션
Publication of KR20110017437A publication Critical patent/KR20110017437A/ko
Application granted granted Critical
Publication of KR101274543B1 publication Critical patent/KR101274543B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020117000640A 2008-06-11 2009-06-11 인간 아드레날린 β３ 수용체 리간드, 이를 포함하는 식품 및 의약품 Expired - Fee Related KR101274543B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008153390 2008-06-11
JPJP-P-2008-153390 2008-06-11
PCT/JP2009/060682 WO2009151094A1 (ja) 2008-06-11 2009-06-11 ヒトアドレナリンβ3受容体リガンド、これを含む食品及び医薬品

Publications (2)

Publication Number Publication Date
KR20110017437A KR20110017437A (ko) 2011-02-21
KR101274543B1 true KR101274543B1 (ko) 2013-06-17

Family

ID=41416798

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117000640A Expired - Fee Related KR101274543B1 (ko) 2008-06-11 2009-06-11 인간 아드레날린 β３ 수용체 리간드, 이를 포함하는 식품 및 의약품

Country Status (7)

Country Link
US (1) US20110098358A1 (enExample)
EP (1) EP2316445A4 (enExample)
JP (2) JP5544660B2 (enExample)
KR (1) KR101274543B1 (enExample)
CN (1) CN102149375B (enExample)
CA (1) CA2727223C (enExample)
WO (1) WO2009151094A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016071180A1 (en) * 2014-11-03 2016-05-12 Nestec S.A. Methods using facial temperature to evaluate post-ingestive impact of food ingredients on fat oxidation
US9561206B2 (en) * 2015-01-07 2017-02-07 The United States Of America, As Represented By The Secretary Of The Navy Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome
AU2018354090B2 (en) 2017-10-23 2024-10-24 Epitracker, Inc. Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
AU2019274431B2 (en) 2018-05-23 2025-03-13 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
WO2020146263A1 (en) 2019-01-09 2020-07-16 Epitracker, Inc. Compositions and methods for diagnosis and treatment of neurodegenerative diseases
JP7404382B2 (ja) 2019-03-04 2023-12-25 エピトラッカー インコーポレイテッド 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用
JP7500037B2 (ja) * 2019-07-24 2024-06-17 国立大学法人 東京大学 血中尿酸値低下剤及び血中尿酸値低下用食品組成物
US12370166B2 (en) 2021-11-03 2025-07-29 Epitracker, Inc. Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008000440A1 (en) * 2006-06-27 2008-01-03 Lipid Nutrition B.V. Use of a polyunsaturated fatty acid compound

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2173545C (en) * 1995-04-07 2004-06-29 Kalyana Sundram Increasing the hdl level and the hdl/ldl ratio in human serum by balancing saturated and polyunsaturated dietary fatty acids
US5578334A (en) * 1995-04-07 1996-11-26 Brandeis University Increasing the HDL level and the HDL/LDL ratio in human serum with fat blends
EP1285590A1 (en) * 2001-08-08 2003-02-26 Société des Produits Nestlé S.A. Lipid blends
US7687074B2 (en) * 2001-08-23 2010-03-30 Westgate Biological Ltd. Use of milk serum apoproteins in the treatment of microbial or viral infection
WO2003099304A1 (en) * 2002-05-27 2003-12-04 Morinaga & Co., Ltd. Composition against periodontal bacteria and foods, drinks and mouth washers against periodontal bacteria containing the composition
JP2004075653A (ja) * 2002-06-19 2004-03-11 Nisshin Oillio Ltd 体脂肪分解促進剤および飲食物
AU2003261926A1 (en) * 2002-09-05 2004-03-29 The Nisshin Oillio Group, Ltd. Slimming agents and foods and drinks comprising the same
JPWO2004022050A1 (ja) * 2002-09-05 2005-12-22 日清オイリオグループ株式会社 脂質代謝調整剤および飲食物
CN1330671C (zh) 2002-10-08 2007-08-08 株式会社利根 含脱乙酰壳多糖的多糖、其制备方法和用途
JP2006096666A (ja) 2002-10-31 2006-04-13 Kaneka Corp 選択的ヒトβ３アドレナリン受容体アゴニスト剤
JP2005015358A (ja) * 2003-06-25 2005-01-20 Pharma Design Inc 摂食障害の治療に供される医薬組成物
AU2004285803A1 (en) * 2003-11-04 2005-05-12 Meiji Dairies Corporation Plant-origin beta3-adrenoceptor agonist and use of the same
JP2005179264A (ja) * 2003-12-19 2005-07-07 Shokubutsu Kogaku Kenkyusho:Kk 体重増加抑制剤
US20060084637A1 (en) * 2004-10-18 2006-04-20 Maria Alemany Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same
EP1834639B8 (en) * 2005-01-04 2016-12-07 Mochida Pharmaceutical Co., Ltd. Remedial agent for fat toxicity
US20080200707A1 (en) * 2005-01-04 2008-08-21 Mochida-Pharmaceuticals Pharmaceutical Co., Ltd. Lipotoxicity Relieving Agent
GB0514463D0 (en) * 2005-01-31 2005-08-17 Loders Croklaan Bv Use of pinolenic acid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008000440A1 (en) * 2006-06-27 2008-01-03 Lipid Nutrition B.V. Use of a polyunsaturated fatty acid compound

Also Published As

Publication number Publication date
CN102149375B (zh) 2015-09-30
JP5544660B2 (ja) 2014-07-09
EP2316445A4 (en) 2011-12-21
JPWO2009151094A1 (ja) 2011-11-17
KR20110017437A (ko) 2011-02-21
US20110098358A1 (en) 2011-04-28
JP2014080432A (ja) 2014-05-08
EP2316445A1 (en) 2011-05-04
CA2727223C (en) 2014-10-07
WO2009151094A1 (ja) 2009-12-17
CN102149375A (zh) 2011-08-10
CA2727223A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
KR101274543B1 (ko) 인간 아드레날린 β３ 수용체 리간드, 이를 포함하는 식품 및 의약품
CN103549410B (zh) 一种肠道黏膜保护与修复型肠内营养制品及其制备方法
CN102586119B (zh) 一种功能红曲菌株及其功能青稞红曲制备方法和应用
JP6483240B2 (ja) 希少ジンセノサイドを高含量で含有する、山参もしくは高麗人参を含む高麗人参類の抽出物または高麗人参類の形成層由来植物幹細胞もしくはその抽出物の製造方法
WO2010021247A1 (ja) セロトニントランスポーター阻害活性を有する医薬品又は飲食品
BR112016025892B1 (pt) Lactobacillus rhamnosus mortos por calor conjugados a um aglutinante de polissacarídeo polimérico, seu método de preparação e seu uso, composição farmacêutica e composição de alimentação
CN103288978B (zh) 岩藻聚糖硫酸酯及其制备方法和在制备抗糖尿病的α-糖苷酶抑制剂中的应用
CN106377533A (zh) 一种海参磷脂及其在提高机体运动协调能力制品中的应用
CN105503988A (zh) 天然抗癫痫活性化合物及其在药物制剂中的用途
WO2018012773A1 (ko) 울다비오시드 a 화합물을 함유하는 항염증 조성물
HK1157216A (en) Human b3 adrenergic receptor ligand, and food or pharmaceutical product containing the same
KR20120008366A (ko) 오미자 추출물로부터 분리된 화합물을 유효성분으로 함유하는 대장염 질환의 예방 및 치료용 조성물
JP2015021001A (ja) 納豆菌を用いたマコンブ発酵物の血圧上昇抑制剤
US20100028465A1 (en) Composition for ameliorating cerebral function
CA2966574A1 (en) Agents for maintaining undifferentiated state and promoting proliferation of stem cells
JP2016204303A (ja) 抗健忘症用組成物
JP2015193547A (ja) 運動様作用を有するレスベラトロール加熱処理組成物
KR102854919B1 (ko) 벼메뚜기 추출물 또는 쌍별귀뚜라미 추출물을 유효성분으로 함유하는 뇌전증의 예방, 개선 또는 치료용 조성물
KR101495607B1 (ko) Ｓ-아릴 시스테인을 유효성분으로 함유하는 비만으로 유도된 염증 치료용 조성물
CN104189219B (zh) 一种中药组合物
JP2019172614A (ja) 遺伝子発現制御剤及び筋委縮の抑制剤、予防剤又は改善剤
EP1915142A1 (en) Composition comprising oleic acid and the use thereof
KR101785970B1 (ko) 올레산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 근육손실 예방 및 치료용 약학적 조성물
CN1223371C (zh) 大花红景天有效成份制剂及制备方法
JP2010059106A (ja) 糖尿病進行抑制作用を有する組成物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

FPAY Annual fee payment

Payment date: 20160602

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20170605

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20190416

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230608

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230608